Clinical applications of mifepristone

  title={Clinical applications of mifepristone},
  author={Oi Shan Tang and Pak-chung Ho},
  journal={Gynecological Endocrinology},
  pages={655 - 659}
  • O. Tang, P. Ho
  • Published 1 January 2006
  • Medicine
  • Gynecological Endocrinology
Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog. It is also an effective cervical priming agent that can be used to soften the cervix before surgical evacuation. Its clinical efficacy as an emergency contraception has been proven. Other applications including treatment for fibroids, endometriosis and… 
Mifepristone (RU486), a pure antiprogesterone drug, in combination with vinblastine for the treatment of progesterone receptor-positive desmoid tumor
Treatment with mifepristone, a pure antiprogesterone drug, was initiated, and partial tumor regression was achieved in a patient who developed a desmoid tumor following total proctocolectomy and J-pouch reconstruction.
Emergency Contraception: An Updated Review
This review analyzes the most common emergency contraception drugs: levonorgestrel, mifepristone and ulipristal acetate about their action underlining that the hormonal products play different roles depending on the phase of the menstrual cycle during which they are administered.
Gynaecological uses of a new class of steroids: the selective progesterone receptor modulators
This review evaluates the actual and potential usefulness of SPRMs in gynaecology.
The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas
The use of mifepristone in abortion will increase the risk to develop uterine leiomyomas, and the risk increased with increasing frequency of m ifeprist one use.
Selective progesterone receptor modulators 1: use during pregnancy
The only applications that seem worthy of large-scale utilisation during pregnancy are voluntary interruption of early and late gestation, medical management of early delayed miscarriage and late foetal demise, and the induction of labour at term.
Medical management of miscarriage
Medical management of miscarriage using a suitable prostaglandin analogue is a safe and effective alternative with high efficacy and patient acceptability and can be routinely offered as an alternative option, thereby increasing women's choice.
Selective progesterone receptor modulators 2: use in reproductive medicine
Few applications outside pregnancy seem worthy of large-scale use: emergency contraception and long-term medical management of uterine fibroids and possibly of endometriosis.
Clinical Research on Efficacy of Cassia Twig Tuckahoe Capsule and Mifepristone Combined with Laparoscopic Surgery for the Treatment of Endometriosis
Cassia twig Tuckahoe capsule combined with Laparoscopy is superior to the Mifepristone combined with laparoscopic surgery for the treatment of endometriosis.
A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies.
  • Lin Mei, Junbo Bao, Hongfan Sun
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2010


Mifepristone: a novel estrogen-free daily contraceptive pill
Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol.
After the administration of mifepristone, vaginal administration of misoprostol is more effective and better tolerated than oral administration for the induction of first-trimester abortion.
Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
It was retrospectively calculated that in 124 cycles at least one act of intercourse occurred during the period 3 days before to 1 day after ovulation, and the probability of pregnancy in this period of the menstrual cycle is 0.008.
Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial.
It was concluded that a standard oral pilot dose of 600 mg of mifepristone induces natural expulsion in 82% of women with non-developing first trimester intrauterine pregnancies.
The use of mifepristone in the treatment of neuropsychiatric disorders